Phase 1 study of EGFR‐antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives

Overview of attention for article published in Cancer (0008543X), October 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 8 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 24 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 9 X posts from 8 X users, with an upper bound of 51,286 followers.

Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. https://t.co/r9eYqyfjj9 H/T @NCBI #radonc #PubMed

24 Sep 2019

Reply Repost Favourite

RT @JournalCancer: Phase 1 study of EGFR‐antisense DNA, cetuximab, and radiotherapy in #HeadAndNeckCancer with preclinical correlatives htt…

12 Oct 2018

Reply Repost Favourite

RT @JournalCancer: Phase 1 study of EGFR‐antisense DNA, cetuximab, and radiotherapy in #HeadAndNeckCancer with preclinical correlatives htt…

11 Oct 2018

Reply Repost Favourite

RT @JournalCancer: Phase 1 study of EGFR‐antisense DNA, cetuximab, and radiotherapy in #HeadAndNeckCancer with preclinical correlatives htt…

11 Oct 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.